Cargando…

Clinical features and outcomes of patients with myositis associated-interstitial lung disease

INTRODUCTION: Myositis associated interstitial lung disease (ILD) seems to be an under-recognized entity. METHODS: In this multicenter, retrospective study, we recorded between 9/12/2019 and 30/9/2021 consecutive patients who presented in five different ILD centers from two European countries (Greec...

Descripción completa

Detalles Bibliográficos
Autores principales: Karampitsakos, Theodoros, Tzilas, Vasilios, Papaioannou, Ourania, Chrysikos, Serafeim, Vasarmidi, Eirini, Juge, Pierre-Antoine, Vizirianaki, Styliani, Bibaki, Eleni, Reppa, Argyro, Sidiropoulos, Prodromos, Katsaras, Matthaios, Sotiropoulou, Vasilina, Tsiri, Panagiota, Koulousousa, Electra, Theochari, Eva, Tsirikos, Georgios, Christopoulos, Ioannis, Malakounidou, Elli, Zarkadi, Eirini, Sampsonas, Fotios, Hillas, Georgios, Karageorgas, Theofanis, Daoussis, Dimitrios, Kalogeropoulou, Christina, Dimakou, Katerina, Tzanakis, Nikolaos, Borie, Raphael, Dieudé, Philippe, Antoniou, Katerina, Crestani, Bruno, Bouros, Demosthenes, Tzouvelekis, Argyris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868310/
https://www.ncbi.nlm.nih.gov/pubmed/36698813
http://dx.doi.org/10.3389/fmed.2022.1096203
_version_ 1784876506037616640
author Karampitsakos, Theodoros
Tzilas, Vasilios
Papaioannou, Ourania
Chrysikos, Serafeim
Vasarmidi, Eirini
Juge, Pierre-Antoine
Vizirianaki, Styliani
Bibaki, Eleni
Reppa, Argyro
Sidiropoulos, Prodromos
Katsaras, Matthaios
Sotiropoulou, Vasilina
Tsiri, Panagiota
Koulousousa, Electra
Theochari, Eva
Tsirikos, Georgios
Christopoulos, Ioannis
Malakounidou, Elli
Zarkadi, Eirini
Sampsonas, Fotios
Hillas, Georgios
Karageorgas, Theofanis
Daoussis, Dimitrios
Kalogeropoulou, Christina
Dimakou, Katerina
Tzanakis, Nikolaos
Borie, Raphael
Dieudé, Philippe
Antoniou, Katerina
Crestani, Bruno
Bouros, Demosthenes
Tzouvelekis, Argyris
author_facet Karampitsakos, Theodoros
Tzilas, Vasilios
Papaioannou, Ourania
Chrysikos, Serafeim
Vasarmidi, Eirini
Juge, Pierre-Antoine
Vizirianaki, Styliani
Bibaki, Eleni
Reppa, Argyro
Sidiropoulos, Prodromos
Katsaras, Matthaios
Sotiropoulou, Vasilina
Tsiri, Panagiota
Koulousousa, Electra
Theochari, Eva
Tsirikos, Georgios
Christopoulos, Ioannis
Malakounidou, Elli
Zarkadi, Eirini
Sampsonas, Fotios
Hillas, Georgios
Karageorgas, Theofanis
Daoussis, Dimitrios
Kalogeropoulou, Christina
Dimakou, Katerina
Tzanakis, Nikolaos
Borie, Raphael
Dieudé, Philippe
Antoniou, Katerina
Crestani, Bruno
Bouros, Demosthenes
Tzouvelekis, Argyris
author_sort Karampitsakos, Theodoros
collection PubMed
description INTRODUCTION: Myositis associated interstitial lung disease (ILD) seems to be an under-recognized entity. METHODS: In this multicenter, retrospective study, we recorded between 9/12/2019 and 30/9/2021 consecutive patients who presented in five different ILD centers from two European countries (Greece, France) and received a multidisciplinary diagnosis of myositis associated-ILD. The primary outcome was all-cause mortality over 1 year in specific subgroups of patients. Secondary outcomes included comparison of disease characteristics between patients diagnosed with the amyopathic subtype and patients with evidence of myopathy at diagnosis. RESULTS: We identified 75 patients with myositis associated-ILD. Median age (95% CI) at the time of diagnosis was 64.0 (61.0–65.0) years. Antinuclear antibody testing was positive in 40% of the cohort (n = 30/75). Myopathy onset occurred first in 40.0% of cases (n = 30), ILD without evidence of myopathy occurred in 29 patients (38.7%), while 16 patients (21.3%) were diagnosed concomitantly with ILD and myopathy. The commonest radiographic pattern was cellular non-specific interstitial pneumonia (NSIP) and was observed in 29 patients (38.7%). The radiographic pattern of organizing pneumonia was significantly more common in patients diagnosed with the amyopathic subtype compared to patients that presented with myopathy [24.1% (n = 7/29) vs. 6.5% (n = 3/46), p = 0.03]. One year survival was 86.7% in the overall population. Kaplan–Meier analysis demonstrated significantly higher all-cause 1-year mortality in patients with the amyopathic subtype compared to patients with evidence of myopathy [H R 4.24 (95% CI: 1.16–15.54), p = 0.03]. Patients diagnosed following hospitalization due to acute respiratory failure experienced increased risk of 1-year all-cause mortality compared to patients diagnosed in outpatient setting [HR 6.70 (95% CI: 1.19–37.81), p = 0.03]. Finally, patients with positive anti-MDA5 presented with higher 1-year all-cause mortality compared to anti-MDA5 negative patients [HR 28.37 (95% CI: 5.13–157.01), p = 0.0001]. CONCLUSION: Specific ILD radiographic patterns such as NSIP and organizing pneumonia may herald underlying inflammatory myopathies. Hospitalized patients presenting with bilateral organizing pneumonia refractory to antibiotics should be meticulously evaluated for myositis associated-ILD even if there is no overt muscular involvement. Incorporation of ILD radiological patterns in the diagnostic criteria of inflammatory myopathies may lead to timely therapeutic interventions and positively impact patients’ survival.
format Online
Article
Text
id pubmed-9868310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98683102023-01-24 Clinical features and outcomes of patients with myositis associated-interstitial lung disease Karampitsakos, Theodoros Tzilas, Vasilios Papaioannou, Ourania Chrysikos, Serafeim Vasarmidi, Eirini Juge, Pierre-Antoine Vizirianaki, Styliani Bibaki, Eleni Reppa, Argyro Sidiropoulos, Prodromos Katsaras, Matthaios Sotiropoulou, Vasilina Tsiri, Panagiota Koulousousa, Electra Theochari, Eva Tsirikos, Georgios Christopoulos, Ioannis Malakounidou, Elli Zarkadi, Eirini Sampsonas, Fotios Hillas, Georgios Karageorgas, Theofanis Daoussis, Dimitrios Kalogeropoulou, Christina Dimakou, Katerina Tzanakis, Nikolaos Borie, Raphael Dieudé, Philippe Antoniou, Katerina Crestani, Bruno Bouros, Demosthenes Tzouvelekis, Argyris Front Med (Lausanne) Medicine INTRODUCTION: Myositis associated interstitial lung disease (ILD) seems to be an under-recognized entity. METHODS: In this multicenter, retrospective study, we recorded between 9/12/2019 and 30/9/2021 consecutive patients who presented in five different ILD centers from two European countries (Greece, France) and received a multidisciplinary diagnosis of myositis associated-ILD. The primary outcome was all-cause mortality over 1 year in specific subgroups of patients. Secondary outcomes included comparison of disease characteristics between patients diagnosed with the amyopathic subtype and patients with evidence of myopathy at diagnosis. RESULTS: We identified 75 patients with myositis associated-ILD. Median age (95% CI) at the time of diagnosis was 64.0 (61.0–65.0) years. Antinuclear antibody testing was positive in 40% of the cohort (n = 30/75). Myopathy onset occurred first in 40.0% of cases (n = 30), ILD without evidence of myopathy occurred in 29 patients (38.7%), while 16 patients (21.3%) were diagnosed concomitantly with ILD and myopathy. The commonest radiographic pattern was cellular non-specific interstitial pneumonia (NSIP) and was observed in 29 patients (38.7%). The radiographic pattern of organizing pneumonia was significantly more common in patients diagnosed with the amyopathic subtype compared to patients that presented with myopathy [24.1% (n = 7/29) vs. 6.5% (n = 3/46), p = 0.03]. One year survival was 86.7% in the overall population. Kaplan–Meier analysis demonstrated significantly higher all-cause 1-year mortality in patients with the amyopathic subtype compared to patients with evidence of myopathy [H R 4.24 (95% CI: 1.16–15.54), p = 0.03]. Patients diagnosed following hospitalization due to acute respiratory failure experienced increased risk of 1-year all-cause mortality compared to patients diagnosed in outpatient setting [HR 6.70 (95% CI: 1.19–37.81), p = 0.03]. Finally, patients with positive anti-MDA5 presented with higher 1-year all-cause mortality compared to anti-MDA5 negative patients [HR 28.37 (95% CI: 5.13–157.01), p = 0.0001]. CONCLUSION: Specific ILD radiographic patterns such as NSIP and organizing pneumonia may herald underlying inflammatory myopathies. Hospitalized patients presenting with bilateral organizing pneumonia refractory to antibiotics should be meticulously evaluated for myositis associated-ILD even if there is no overt muscular involvement. Incorporation of ILD radiological patterns in the diagnostic criteria of inflammatory myopathies may lead to timely therapeutic interventions and positively impact patients’ survival. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868310/ /pubmed/36698813 http://dx.doi.org/10.3389/fmed.2022.1096203 Text en Copyright © 2023 Karampitsakos, Tzilas, Papaioannou, Chrysikos, Vasarmidi, Juge, Vizirianaki, Bibaki, Reppa, Sidiropoulos, Katsaras, Sotiropoulou, Tsiri, Koulousousa, Theochari, Tsirikos, Christopoulos, Malakounidou, Zarkadi, Sampsonas, Hillas, Karageorgas, Daoussis, Kalogeropoulou, Dimakou, Tzanakis, Borie, Dieudé, Antoniou, Crestani, Bouros and Tzouvelekis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Karampitsakos, Theodoros
Tzilas, Vasilios
Papaioannou, Ourania
Chrysikos, Serafeim
Vasarmidi, Eirini
Juge, Pierre-Antoine
Vizirianaki, Styliani
Bibaki, Eleni
Reppa, Argyro
Sidiropoulos, Prodromos
Katsaras, Matthaios
Sotiropoulou, Vasilina
Tsiri, Panagiota
Koulousousa, Electra
Theochari, Eva
Tsirikos, Georgios
Christopoulos, Ioannis
Malakounidou, Elli
Zarkadi, Eirini
Sampsonas, Fotios
Hillas, Georgios
Karageorgas, Theofanis
Daoussis, Dimitrios
Kalogeropoulou, Christina
Dimakou, Katerina
Tzanakis, Nikolaos
Borie, Raphael
Dieudé, Philippe
Antoniou, Katerina
Crestani, Bruno
Bouros, Demosthenes
Tzouvelekis, Argyris
Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title_full Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title_fullStr Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title_full_unstemmed Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title_short Clinical features and outcomes of patients with myositis associated-interstitial lung disease
title_sort clinical features and outcomes of patients with myositis associated-interstitial lung disease
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868310/
https://www.ncbi.nlm.nih.gov/pubmed/36698813
http://dx.doi.org/10.3389/fmed.2022.1096203
work_keys_str_mv AT karampitsakostheodoros clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT tzilasvasilios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT papaioannouourania clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT chrysikosserafeim clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT vasarmidieirini clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT jugepierreantoine clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT vizirianakistyliani clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT bibakieleni clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT reppaargyro clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT sidiropoulosprodromos clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT katsarasmatthaios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT sotiropoulouvasilina clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT tsiripanagiota clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT koulousousaelectra clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT theocharieva clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT tsirikosgeorgios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT christopoulosioannis clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT malakounidouelli clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT zarkadieirini clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT sampsonasfotios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT hillasgeorgios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT karageorgastheofanis clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT daoussisdimitrios clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT kalogeropoulouchristina clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT dimakoukaterina clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT tzanakisnikolaos clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT borieraphael clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT dieudephilippe clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT antonioukaterina clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT crestanibruno clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT bourosdemosthenes clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease
AT tzouvelekisargyris clinicalfeaturesandoutcomesofpatientswithmyositisassociatedinterstitiallungdisease